Nobis Nobis Cartel windows 7 home premium activation key 70-290

Managing the Immunodulators

A questionDosage and indication “creep” with the new biologics to treat inflammatory diseases have payers enforcing strict utilization policies. Physicians counter that payers can’t dictate treatment. With even more biologics on the horizon, and drug spend spiralling upward, both sides need to seek a middle ground. The question is how?

“It’s a bit like solving a Rubik’s Cube” when dealing with new immunomodulators, says Helen Sherman, PharmD, with RegenceRX. “We keep track of all the science and potential uses, but this is a complex category.”

read the rest of this story at: http://www.biotechnologyhealthcare.com/journal/fulltext//7/2/BH0702012.pdf

Publié dans Dans le monde entier

REJOIGNEZ AUJOURD'HUI!

Le registre de P/P a été approuvé par la Commission d'examen institutionnel ouest (WIRB) et est activement inscription des participants.

VERSION ANGLAISE